<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decreased&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is believed to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA can have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is observed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is shown to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA may have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Disruption of narL is able to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Disruption of narL is believed to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Disruption of narL was shown to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is able to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Lipid peroxide synthesis can have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Lipid peroxide synthesis has been decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Lipid peroxide synthesis is able to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Lipid peroxide synthesis may have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity will be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Nitrite induction of the nirB promoter has been decreased by disruption of narL which has not been suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Nitrite induction of the nirB promoter is able to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Nitrite induction of the nirB promoter is decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Nitrite induction of the nirB promoter was believed to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>The levels of Clara cell secretory protein was shown to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>The levels of Clara cell secretory protein would be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>The production of C51 microcin was believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>The production of C51 microcin was believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Treatment with melatonin may decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Treatment with melatonin was able to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Treatment with melatonin was believed to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli may have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli would be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL has significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL can significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL could significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is observed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin would significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is shown to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis might be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter can be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter may be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was believed to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin will have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Disruption of narL could decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and the RELN mRNA content can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was able to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus could decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus will decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>overexpression of ArcA has decreased glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>overexpression of ArcA is shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>overexpression of ArcA is shown to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>overexpression of ArcA may decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>overexpression of ArcA was shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>promoter activity in cardiomyocytes might be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>promoter activity in cardiomyocytes will have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>their mutation has the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>their mutation may decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and the protection is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and levels of Clara cell secretory protein could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the protection will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
